12:00 AM
 | 
Dec 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Truvada emtricitabine/tenofovir: Phase III data

Researchers at the J. David Gladstone Institutes and colleagues reported data from the double-blind, international Phase III iPrEx trial in 2,499 HIV-seronegative men who have sex with men showing that pre-exposure prophylaxis with once-daily 200/300 mg oral Truvada emtricitabine/tenofovir met the primary endpoint of significantly reducing the incidence of...

Read the full 222 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >